JUL 11, 2018 2:13 AM PDT

'Acetazolamide' Used To Treat Altitude Sickness, Slows Down the Development of Glioblastoma

WRITTEN BY: Nouran Amin

 

 

Acetazolamide, which is sold under the trade name Diamox and used to treat altitude sickness, is considered inexpensive to manufacture and easy to administer.

"I take it myself, whenever I go to the Rocky Mountains," explains study director Bahktiar Yamini, MD, a professor of neurosurgery at the University of Chicago Medicine. Although acetazolamide has minimal side effects, users report "a metallic taste when drinking something carbonated."

Acetazolamide is a studied to be a carbonic anhydrase inhibitor drug that can restore another drug's ability to eradicate tumor cells.

More specifically, acetazolamide when added to a drug called temozolomide (TMZ), it was seen to slow down the progression of glioblastoma in mouse models.

Acetazolamide enables TMZ to damage the DNA present in tumor cells in order to inhibit its growth.

Researchers discovered that glioblastoma patients with increased levels of a protein called BCL-3 (B cell CLL/lymphoma 3) were unresponsive to the effects exerted by the chemotherapeutic drug, TMZ. In particular, BCL-3 protects cancer cells from TMZ damage by activating a protective enzyme known as carbonic anhydrase II.

"We tested this combination treatment strategy in several animal models," Yamini said. “It cured some of them. Others had a 30 to 40 percent increase in survival time.”

Furthermore, the researchers examined BCL-3 levels from earlier human studies and found that patients with lower levels of BCL-3 who were treated with TMZ had a higher survival rate than patients who had high levels of this biomarker.

"An important feature of predictors like BCL-3 is that they are informative," the authors note. "They can identify pathways to improve treatment response."

By studying those pathways, carbonic anhydrase inhibitors were identified, such as acetazolamide, as a way to decrease the resistance to temozolomide.

"Our data," they note, demonstrate that it is the "induction of CAII by TMZ that is important in modulating response to therapy."

Confirming the use of BCL-3 to predict which patients will benefit from the use of temozolomide will require validation through clinical trials.

Additionally, the authors believe that repurposing the use of acetazolamide along with temozolamide might be particularly effective for patients with tumors that have high BCL-3 expression.

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 20, 2020
Drug Discovery & Development
APR 20, 2020
First Successful Vaccine for Middle-East Respiratory Syndrome
Researchers have successfully completed the first-in-human clinical trial for a vaccine against MERS (Middle East Respir ...
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Preventing Blindness in Premature Births
The premature birth of infants places them at risk for blindness because of retinopathy of prematurity (ROP). To prevent ...
MAY 06, 2020
Drug Discovery & Development
MAY 06, 2020
Why Doctors are Repurposing Drugs to Treat COVID-19
Creating a drug from scratch is a lengthy process. Often taking years, given the rate of infection and deadliness of COV ...
MAY 12, 2020
Drug Discovery & Development
MAY 12, 2020
Does Herbal Drink from Madagascar Cure COVID-19?
Andry Rajoelina, the president of Madagascar, an island off the coast of Southern Africa, has made claims that his count ...
MAY 21, 2020
Cancer
MAY 21, 2020
A New Player in the Regulation of Cancer's Microenvironment
Breast cancer is one of the most common cancers in the world.  Triple-negative breast cancer (TNBC) is a sub-type o ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Drug Targets Off Episodes of Parkinson
A novel drug was approved by the FDA to target the “off” episodes of Parkinson disease. The drug is referred ...
Loading Comments...